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CD4
 
 
 
CD25
 
 
 
 regulatory T cells (T reg cells) play a key role in controlling autoimmunity and 
inflammation. Therefore, therapeutic agents that are capable of elevating numbers or 
increasing effector functions of this T cell subset are highly desirable. In a previous report 
we showed that a superagonistic monoclonal antibody specific for rat CD28 (JJ316) expands 
and activates T reg cells in vivo and upon short-term in vitro culture. Here we demonstrate 
that application of very low dosages of the CD28 superagonist into normal Lewis rats is 
sufficient to induce T reg cell expansion in vivo without the generalized lymphocytosis 
observed with high dosages of JJ316. Single i.v. administration of a low dose of the CD28 
superagonist into Dark Agouti (DA) rats or Lewis rats that suffered from experimental 
autoimmune encephalomyelitis (EAE) proved to be highly and equally efficacious as high-dose 
treatment. Finally, we show that T reg cells that were isolated from CD28-treated animals 
displayed enhanced suppressive activity toward myelin basic protein–specific T cells in vitro, 
and, upon adoptive transfer, protected recipients from EAE. Our data indicate that this class 
of CD28-specific monoclonal antibodies targets CD4
 
 
 
CD25
 
 
 
 T reg cells and provides a novel 
means for the effective treatment of multiple sclerosis and other autoimmune diseases.
 
Immunologic self-tolerance is maintained by
several mechanisms, including negative selec-
tion of autoreactive T cells in the thymus and
peripheral regulatory mechanisms, such as anergy
induction, ignorance, or dominant suppression
by regulatory T cells (T reg cells; reference 1).
Among the different T reg cell populations in-
vestigated so far, CD4
 
 
 
CD25
 
 
 
 T reg cells—the
so-called “naturally occurring” T reg cells—
play a key role in the control of immune re-
sponses  to self-antigens (2–5). Reduced fre-
quencies or impaired function of this T reg cell
population leads to a wide range of autoim-
mune disorders in animals (6) and putatively
also in humans (7–10); this indicated that an im-
balance between T reg cells and autoreactive T
cells may contribute to the pathogenesis of such
diseases. Thus, reagents that are capable of ex-
panding the pool of CD4
 
 
 
CD25
 
 
 
 T cells and
enhancing their suppressive activity should
prove to be very efficient therapeutic tools.
We previously described a novel class of
superagonistic CD28-specific monoclonal an-
tibodies that can induce the in vitro and in
vivo expansion of T cells without a need for
TCR engagement (11–13). The dramatic
polyclonal T cell response after in vivo appli-
cation of a CD28 superagonist (JJ316) is well tol-
erated and not accompanied by a toxic cytokine
storm of proinflammatory mediators, a finding
we have previously attributed to the induction
of counter-regulatory anti-inflammatory cy-
tokines, such as IL-10 (14). Moreover, we
could demonstrate that superagonistic mAbs to
CD28 are capable of expanding functional
CD4
 
 
 
CD25
 
 
 
 T reg cells (15), suggesting that
CD28 superagonist therapy may be highly effec-
tive in the treatment of inflammatory and au-
toimmune diseases.
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In the present report, we show that in vivo application
of the superagonistic mAb JJ316 to Lewis rats causes prefer-
ential expansion of T reg cells over conventional T cells
(T
 
conv
 
 cells), and enhances their suppressive activity. The
administration of very low dosages of the CD28 superago-
nist in vivo allowed us to segregate T reg cell expansion and
activation from the generalized lymphocytosis that was ob-
served with high dosages. By making use of experimental
autoimmune encephalomyelitis (EAE), an animal model for
human multiple sclerosis (MS), we showed that superago-
nistic CD28-specific mAbs are highly efficacious in treating
a prototypic autoimmune disease. Furthermore, in vitro
suppression assays with encephalitogenic T cells, and adop-
tive transfer of T reg cells in vivo indicated that this thera-
peutic effect is mediated by the in vivo activation of
CD4
 
 
 
CD25
 
 
 
 T reg cells.
 
RESULTS
In vivo expansion of T reg cells by CD28 superagonists
 
In previous reports, we showed that application of JJ316 to
normal Lewis rats led to a dramatic, but transient, expansion of
T
 
conv
 
 and T reg cells with a clear preference for T reg cell ex-
pansion (11, 15). This suggested that T reg cells may be more
sensitive to superagonistic CD28 stimulation than conventional
CD4 T cells. Accordingly, we analyzed the effects of different
doses of CD28 superagonist on the expansion and function of
T reg and T
 
conv
 
 cells in vivo. Normal Lewis rats were treated
with control antibody MOPC-31C or with the CD28 super-
agonist JJ316 at doses ranging from 0.1 to 1 mg antibody per
animal. 3 d later, spleen and lymph node cells (LNCs) were
isolated from these animals. T cell subsets defined by CD25 ex-
pression were analyzed by flow cytometry (Fig. 1 A), and rela-
tive and absolute cell numbers for all doses of antibody injected
Figure 1. In vivo dose-response titration of mAb JJ316. Adult Lewis 
rats were injected i.v. with the three indicated amounts of mAb JJ316. 
3 d after injection, peripheral LNCs and splenocytes were analyzed for 
the prevalence of CD4 CD25  and CD4 CD25  cells by FACS analysis. 
(A) Representative dot plots of CD4 and CD25 expression in lymph nodes 
and spleens of control or JJ316-treated animals; the figure indicates the 
percentages of cells in the respective quadrant. (B) The proportion of 
CD25  among CD4  cells is summarized for all animals analyzed. Absolute 
cell numbers were obtained by multiplying total cell numbers with the 
relative cell numbers obtained by FACS analysis (C). The plots in (B) and (C) 
show pooled data obtained on eight different occasions. Each circle repre-
sents one animal (i.e., 2 to 12 animals per group). Horizontal bars indicate 
medians. Mann-Whitney rank sum tests were performed between groups 
as indicated by the brackets, and the respective P values are given. 
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were calculated (Fig. 1, B and C). Fig. 1 B shows that as little as
0.1 mg of JJ316 per animal (0.5 mg/kg body weight) led to a
significant increase in the percentage of CD25
 
 
 
 cells among
CD4
 
 
 
 cells in peripheral lymph nodes and in the spleen. Abso-
lute cell numbers of CD4
 
 
 
CD25
 
 
 
 T cells were increased sig-
nificantly after injection of low amounts of the antibody (0.1
mg and 0.3 mg; Fig. 1 C), whereas CD4
 
 
 
CD25
 
 
 
 cells did not
show a significant change in numbers in this dose range. Only
upon injection of 1 mg (Fig. 1 C) or more (unpublished data)
of mAb JJ316, a significant and very pronounced increase in
CD4
 
 
 
CD25
 
 
 
 T cell numbers was observed; this is in accor-
dance with our previous observations (11). These data indicate
that low doses of CD28 superagonists drive T reg cell prolifer-
ation in vivo without expanding the pool of T
 
conv
 
 cells.
 
Direct monitoring of T reg cell proliferation in vivo
 
To track the in vivo proliferative response of T reg cells after
application of the CD28 superagonist directly, we isolated
CD4
 
 
 
CD25
 
 
 
 and CD4
 
 
 
CD25
 
 
 
 T cells, labeled them ex
vivo with carboxyfluorescein diacetate succinimidyl ester
(CFSE), and reinjected them i.v. into syngeneic normal Lewis
rats. After 18 h the rats received a single i.v. injection of 0.1
mg of superagonistic CD28–specific mAb or control mAb
MOPC-31C. When anti–CD28-treated rats were analyzed at
day three after transfer, 40% of CFSE-labeled CD4
 
 
 
CD25
 
 
 
T cells and 64% of transferred CD4
 
 
 
CD25
 
 
 
 T cells had un-
dergone one or more cell divisions (Fig. 2 A). The marked
CFSE dilution that was observed among transferred T reg
cells provides direct evidence that JJ316 is capable of driving
the proliferation of CD4
 
 
 
CD25
 
 
 
 T reg cells in vivo
 
.
 
In the same experiment, we also determined CD25 expres-
sion on transferred T
 
conv
 
 cells and T reg cells (Fig. 2 B).
CD25
 
 
 
CD4
 
 
 
 T cells failed to express CD25 upon CD28
treatment in vivo (Fig. 2 B), whereas transferred T reg cells
further up-regulated CD25 expression on the cell surface (Fig.
2 B). Because 0.1 mg of JJ316 was not sufficient to induce very
Figure 2. Direct monitoring of T reg and Tconv cell proliferation 
upon superagonistic anti-CD28 stimulation in vivo. T reg and Tconv 
cells were purified from pooled spleens and lymph nodes, labeled with 
CFSE, and adoptively transferred into syngeneic recipients. 0.1 mg of mAb 
JJ316 or control mAb MOPC-31C was injected on the following day. CFSE 
dilution was analyzed 2 d after antibody injection (A). Percentages repre-
sent the proportion of undivided cells among transferred cells. The result 
of one of at least three experiments is shown. (B) CD25 expression on 
transferred T reg and Tconv cells isolated from MOPC-31C–treated or JJ316-
treated animals was determined by counter-staining with anti-CD25 mAb. 
(C) CFSE dye dilution among, and CD25 expression on, Tconv cells were 
assessed after stimulation with 1 mg of JJ316. 
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significant proliferation of T
 
conv
 
 cells, we also monitored CFSE
dye dilution among, and CD25-expression, on T
 
conv
 
 cells after
stimulation with 1 mg JJ316 in vivo (Fig. 2 C). With this dose,
97% of T
 
conv
 
 cells had undergone at least one cell division, but,
again, without detectable induction of CD25 expression on
these cells (Fig. 2 C; reference 15). Therefore, the increased
number of CD4
 
 
 
CD25
 
 
 
 T cells after JJ316 stimulation in vivo
clearly reflects the expansion of preexisting CD4
 
 
 
CD25
 
 
 
 cells.
 
Phenotype and function of in vivo expanded CD4
 
 
 
CD25
 
 
 
 
 
T reg cells
 
To characterize the phenotype of conventional and T reg cell
populations thoroughly, we stained lymph node and spleen
cells from PBS- or JJ316-treated animals for CD4, CD25,
CTL-associated antigen 4 (CTLA-4), and FoxP3 expression
(Fig. 3). The forkhead transcription factor FoxP3 is the most
specific marker for T reg cells (16–19). In lymph node and
spleen of PBS- or CD28 superagonist–treated rats, FoxP3
was expressed almost exclusively by CD4
 
 
 
 cells (i.e., 80–90%
of FoxP3
 
 
 
 cells coexpress CD4; unpublished data). In pe-
ripheral lymph nodes and the spleen of JJ316-injected ani-
mals, the vast majority (80–90%) of CD4
 
 
 
CD25
 
 
 
 cells, and
all CD4
 
 
 
CD25
 
high
 
 cells, continued to express FoxP3 (Fig. 3
A). We corroborated the flow cytometric data by visualizing
FoxP3 expression by Western blot analysis. FoxP3 protein
was detected readily in CD4
 
 
 
CD25
 
 
 
 T reg cells that were
isolated from untreated or JJ316-treated animals. However,
there was no detectable signal originating from CD4
 
 
 
CD25
 
 
 
T cells regardless of whether JJ316 had been applied (Fig. 3
B). In addition to FoxP3, naturally occurring T reg cells con-
stitutively express CTLA-4 (20, 21). Experiments with hu-
man T reg cell clones further showed that expression of
CTLA-4 positively correlated with their suppressive capacity
(22, 23). Therefore, we determined the expression of CTLA-4
by CD4
 
 
 
CD25
 
 
 
FoxP3
 
 
 
 cells from PBS- or JJ316-treated
animals. As compared with PBS-treated control rats,
CD4
 
 
 
CD25
 
 
 
FoxP3
 
 
 
 cells from animals that were injected
with JJ316 revealed strongly enhanced expression of CTLA-4
(Fig. 3 C). The coexpression of FoxP3 and high amounts of
CTLA-4 indicated that phenotypic and functional character-
istics of T reg cells were maintained in JJ316-expanded
CD4
 
 
 
CD25
 
 
 
 T cells.
To prove that the CD25
 
 
 
CD4
 
 
 
 cells that were recov-
ered after superagonistic CD28 treatment were T reg cells,
we tested their suppressive capabilities in ex vivo suppres-
sion assays. 3 d after injection of JJ316 (0.1 or 1 mg per ani-
mal) or PBS into normal Lewis rats, CD4
 
 
 
CD25
 
 
 
 and
CD4
 
 
 
CD25
 
 
 
 T cells from peripheral lymph nodes were as-
sayed for their ability to inhibit the proliferation of CFSE-
labeled CD4
 
 
 
 indicator T cells induced by classical costimu-
lation. Subsequent analysis of CFSE dye dilution revealed a
pronounced proliferation of indicator cells in the absence of
CD4
 
 
 
CD25
 
 
 
 T cells (Fig. 4 A; gray curves). Coculture of
indicator cells with CD4
 
 
 
CD25
 
 
 
 T cells (black curves) that
were isolated from the PBS-treated animal led to partial in-
hibition of indicator cell proliferation. The inhibitory activ-
Figure 3. Phenotypic analysis of T reg and Tconv cells from treated 
animals. 3 d after administration of 1 mg JJ316, lymph node and spleen 
cells were stained at the cell surface with mAbs against CD4 and CD25, 
followed by intracellular staining for FoxP3 and CTLA-4. Control animals 
were injected with PBS only. (A) Representative expression of CD25 and 
FoxP3 on gated CD4  cells. The figure indicates the percentages of cells 
in the respective quadrant. (B) Detection of FoxP3 expression by Western 
blot analysis. CD4 CD25  and CD4 CD25  T cells were purified from 
untreated or JJ316-treated animals (1 mg), and protein lysates from whole 
cells were generated. FoxP3 expression was detected with a polyclonal 
rabbit-anti–mouse FoxP3 IgG. Lysates from cells purified after JJ316 treat-
ment also were diluted serially and protein loading was assessed with 
polyclonal anti–rat ERK-2 Ig. The experiment was repeated with a similar 
result. (C) Representative anti–CTLA-4 staining profiles of CD4 CD25 FoxP3  
cells are depicted (filled line graphs). Staining specificity was controlled by 
preincubation with unconjugated anti–CTLA-4 mAb (gray profile). A repeat 
experiment rendered similar results.
 
ity of CD4
 
 
 
CD25
 
 
 
 T cells that were derived from JJ316-
treated animals was more pronounced after low-dose treat-
ment, and was enhanced dramatically after high-dose treat- 
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ment (Fig. 4, A and B). In accordance with our phenotypic
analysis, CD4
 
 
 
CD25
 
 
 
 T cells did not display immunoregu-
latory capacities after JJ316 treatment. Taken together, our
results show that high- and low-dose superagonistic CD28
treatment increase the pool of naturally occurring T reg
cells, and enhance their suppressive effector functions.
 
Superagonistic CD28–specific mAbs ameliorate disease 
activity in EAE
The results outlined so far suggested that, as a first step, ap-
plication of CD28 superagonists into models for human au-
toimmune diseases might have beneficial effects. Thus, we
investigated the protective effect of JJ316 in different rat
EAE models. First, we focused on preventive or therapeutic
application of JJ316 in the relapsing EAE model in Dark
Agouti (DA) rats that were immunized with recombinant
human myelin oligodendrocyte glycoprotein (MOG). Rats
were treated i.v. on day 0 (disease induction), day 10 (disease
onset), or on days 0 and 10 with 1 mg JJ316 (Fig. 5 A). Con-
trol animals received 1 mg of the isotype-matched mAb
MOPC-31C at the same time points. Preventive administra-
tion of 1 mg JJ316 at the time point of active EAE induction
(day 0) in DA rats led to almost complete suppression of the
first disease episode of EAE. Only delayed and mild signs of
disease were observed. Dual injection of JJ316 on days 0 and
10 protected DA rats even more effectively during the first
disease stage. Therapeutic injection of JJ316 at the time of
disease onset on day 10 immediately ameliorated disease ac-
tivity, and the animals underwent remission significantly ear-
lier compared with control animals. In contrast to the other
regimens, therapeutic application at day 10 did not protect
from severe signs of the disease during the subsequent re-
lapse. Protection from clinical signs of EAE by the CD28 su-
peragonist was accompanied by a decrease in T cell and
macrophage infiltrates into the spinal cord and prevention of
demyelination (Fig. S1, available at http://www.jem.org/
cgi/content/full/jem.20051060/DC1).
Next, we wanted to determine the minimal effective
dose of JJ316 and, therefore, treated DA rats after onset of
MOG-EAE with 0.03 mg, 0.1 mg, or 0.3 mg per animal
(Fig. 5 B). The maximal therapeutic effect of JJ316 was
achieved at 0.3 mg; however, a dose as small as 0.03 mg was
effective in reducing the severity of EAE (P   0.05). Ad-
ministration of 0.1 mg of the conventional CD28 mAb JJ319
had no effect on disease manifestation, with clinical scores
comparable to those of MOPC-31C–treated controls.
To assess whether protection by CD28 superagonists may
have a wider application beyond MOG-induced EAE in the
DA rat, we also induced EAE in Lewis rats by immunizing
them with guinea pig myelin basic protein (gpMBP) in CFA.
11 d later (i.e., after onset of disease), the rats received a single
injection of JJ316 at different dosages (0.1, 0.3, and 1 mg/
animal) or an isotype control antibody (MOPC-31C, 1 mg/
animal). In analogy to standard treatment schemes applied in
human autoimmune diseases, including MS (24), another
group of rats received daily treatment with 2 mg of methyl-
prednisolone from days 11 to 15 after immunization. We ob-
served a clear reduction of disease activity (Fig. 5 C) in all rats
that had received CD28 superagonist treatment, whereas the
glucocorticosteroid had a comparatively weaker impact on
the clinical course of the disease.
Our findings demonstrate the efficacy of superagonistic
anti-CD28 in two independent models of EAE, and show
that it is superior to standard glucocorticoid treatment.
Moreover, protection by CD28 superagonist application also
was observed in the adoptive transfer model of Lewis rat-
EAE—a model that mimics a very aggressive type of au-
toimmune disease where there is no active induction of
pathogenic T cells (Fig. S2, available at http://www.jem.
org/cgi/content/full/jem.20051060/DC1).
Figure 4. Functional analysis of T reg and Tconv cells from JJ316-
treated animals ex vivo. (A) Purified T reg and Tconv cells from the lymph 
nodes of animals treated as indicated 3 d before isolation were cocultured 
with CFSE-labeled CD4 CD25  T cells from the PBS-treated animal (indi-
cator T cells), and stimulated with costimulatory beads for 5 d. Line graphs 
show proliferations of indicator T cells in the absence (gray shadow) or the 
presence of T reg or Tconv cells at a 1:1 ratio (black line). (B) T reg and Tconv 
cell/indicator T cell ratios of 1:1, 1:5, and 1:10 were determined by trans-
lating CFSE dilution profiles into the average number of cell divisions of 
the indicator T cells after 5 d of culture. The symbols indicate proliferation 
of indicator T cells in the absence of T reg/Tconv cells (open diamonds) or in 
the presence of T reg/Tconv cells from the animal treated with PBS (filled 
circles), 0.1 mg JJ316 (open squares), or 1 mg JJ316 (gray diamonds). The 
result is representative of two experiments performed.MODULATION OF EAE WITH CD28 SUPERAGONISTS | Beyersdorf et al. 450
CD28 superagonist activated T reg cells suppress myelin 
basic protein (MBP)–directed T cell responses in vitro
Encephalitogenic (myelin basic protein specific) CD4  T
cells play a pivotal role in initiating and maintaining EAE
(25). Hence, one mechanism underlying the therapeutic ef-
fect of CD28 superagonists on EAE could be the successful
suppression of these pathogenic T cells by activated and ex-
panded CD4 CD25  T reg cells. Therefore, we tested
whether CD4 CD25  T reg cells that are stimulated by the
CD28 superagonist in vivo could suppress MBP-driven T
cell proliferation in vitro. For in vivo priming, we immu-
nized Lewis rats with gpMBP, and treated them 6 d later
with PBS or JJ316 (0.1 or 1 mg per animal). After another
3 d we isolated CD4 CD25  and CD4 CD25  T cells
from the PBS- or JJ316-treated animals, and cocultured the
cells with CD4 CD25  indicator cells (derived from the
PBS-treated control animal) in the presence of irradiated
splenic APCs and gpMBP. We did not observe any sup-
pressive activity toward MBP-driven T cell proliferation of
CD4 CD25  T reg cells that were isolated from the PBS-
treated animal (Fig. 6). In contrast, significant, or even very
strong, suppression was detectable using CD4 CD25  T reg
cells that were derived from the animals that were treated
with 0.1 mg or 1 mg of the CD28 superagonist, respectively
(Fig. 6). CD4 CD25  T cells that were isolated from either
treatment group proliferated in response to gpMBP stimula-
tion, and failed to suppress antigen-specific indicator T cells.
These results show that CD4 CD25  T reg cells activated
by CD28 superagonists in vivo are potent suppressors of
Figure 5. Therapeutic potential of superagonistic CD28-specific 
mAb JJ316 on active EAE of the Lewis and the DA rat. (A) To 
induce EAE in DA rats, animals were immunized with 100  g recombi-
nant human MOG in CFA at day 0. mAb JJ316 (1 mg) was administered 
i.v. to groups of animals (n   8) at day 0 (induction of EAE, open 
squares), day 10 (onset of EAE, open circles), or on days 0 and 10 (open 
triangles). Control animals (n   5) were injected with 1 mg of MOPC-31C 
at the different time points as indicated. Animals were scored for clin-
ical signs of EAE as described in Material and methods. (B) Therapeutic 
application of 0.3 mg, 0.1 mg, or 0.03 mg of JJ316 after onset of 
disease (day 10, arrow) protected DA rats (n   6) immediately from 
severe EAE. Control animals were injected with 0.3 mg of MOPC-31C 
or 0.1 mg of the conventional anti-CD28 mAb JJ319. Mann-Whitney 
U-tests comparing JJ316- and sham-treated rats on days 13 and 14 
after disease onset were significant (P   0.05) for animals receiving 
0.03 mg of JJ316 and highly significant (P   0.01) for animals receiv-
ing 0.3 mg of JJ316. (C) Active EAE of the Lewis rat was induced by 
immunization with gpMBP in CFA in the hind footpad at day 0. On 
day 11 (arrow), animals received a single injection of 1 mg of an isotype 
control antibody (filled circles); a single injection of 0.1 mg, 0.3 mg, or 
1 mg of mAb JJ316; or were administered 2 mg of methylprednisolone 
on five consecutive days. P values of Mann-Whitney rank sum tests of 
clinical scores that compared the isotype-treated group with the 
JJ316-treated groups on days 13, 14, and 15 were all significant; most 
were highly significant.
Figure 6. mAb JJ316-primed T reg cells suppress the proliferation 
of gpMBP-specific T cells in vitro. T reg and Tconv cells were isolated 
from the draining lymph nodes of animals that had been immunized with 
gpMBP in CFA 9 d before functional analysis. mAb JJ316 (0.1 mg or 1 mg 
per animal) or PBS was administered 3 d before the in vitro suppression 
assay. Conventional CD4 CD25  T cells from the PBS-treated animal (gray 
bars) served as indicator T cells, and were cocultured with T reg or Tconv 
cells from the animal treated with PBS, 0.1 mg JJ316, or 1 mg of JJ316. 
T cells were stimulated with gpMBP in the presence of irradiated splenic 
APCs. A repeat experiment rendered similar results.JEM VOL. 202, August 1, 2005 451
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polyclonal T cell proliferation and mediate profound inhibi-
tion of antigen-specific T cell responses.
Transfer of protection from EAE by activated CD4 CD25  
T cells from CD28 superagonist–treated animals
To identify directly a potential contribution of JJ316-acti-
vated T reg cells to the therapeutic effects observed in vivo,
we primed donor rats with 1 mg anti-CD28 superagonist,
and immunized them together with gpMBP in CFA. 3 d af-
ter priming, recipient animals received 4 (4.7)   107 total
LNCs (containing  10% CD4 CD25  T cells), 4 (4.7)  
106 sorted CD4 CD25  T cells, or 3.6 (4.2)   107
CD4 CD25  T cells on the day of active EAE or adoptive
transfer (AT)-EAE induction (Fig. 7, A and B); numbers in
parentheses denote the amount of cells transferred in AT-
EAE (Fig. 4 B). Compared with control rats, which were in-
jected with PBS only, clinical signs of active EAE and AT-
EAE in recipients of total LNCs or of the respective fraction
of CD4 CD25  JJ316-primed T cells were mitigated signifi-
cantly (ANOVA: P   0.001). In contrast, the adoptive trans-
fer of CD4 CD25 -JJ316 primed T cells did not alter EAE
severity, which suggested that CD4 CD25  T reg cells con-
stitute the protective cell population within whole LNCs.
To investigate the impact of antigen during the recruit-
ment of T reg cells by the application of superagonistic anti-
CD28 mAb in vivo, nonimmunized donors received 1 mg
of JJ316 3 d before isolation of LNCs (Fig. 7 C). This time,
6   107 unsorted total LNCs, 6   106 CD4 CD25  lym-
phocytes, or 5.4   107 CD4 CD25  lymphocytes were
transferred i.v. into Lewis rats that were immunized with
gpMBP in CFA. Transfer of total JJ316-primed LNCs re-
sulted in a significantly milder disease course (ANOVA: P  
0.05). Transfer of CD4 CD25  T cells resulted in a highly
significant amelioration of EAE signs (ANOVA: P   0.0001).
The transfer of CD4 CD25  T cells did not lead to signifi-
cant alteration of EAE as compared with controls. This
showed that the superagonistic CD28–specific mAb has
the potency to activate EAE-protective CD4 CD25  T reg
cells—even in the absence of exogenously provided anti-
gen—presumably by activating “natural” T reg cells with a
preselected self-specific repertoire (26).
DISCUSSION
In our previous work (15) we showed that superagonistic
CD28–specific antibodies preferentially expanded pre-
existing CD4 CD25  T reg cells because conventional
CD4 CD25  T cells are not recruited into the pool of
CD25  cells upon JJ316 stimulation in vivo. We confirmed
this result in the present study (Fig. 2), and bypassed the pit-
falls that are involved in using only CD25 as a marker for T
reg cells by determining FoxP3 expression at the single cell
CD4 CD25  T cells (open circles). Control treatment consisted of the 
transfer of 5.4   107 CD28 superagonist-activated CD4 CD25  T cells 
(gray circles) or in the administration of PBS only (black circles).
Figure 7. CD4 CD25  T reg cells mediate reduced disease severity. 
Donor animals were immunized with gpMBP in CFA and received 1 mg of 
mAb JJ316 i.v. 3 d later, draining LNCs were prepared and separated, in 
part, into CD4 CD25  and CD4 CD25  cells. Recipient animals received 
PBS only, 4 (4.7)   107 total draining LNCs, 4 (4.7)   106 purified CD4 CD25  
T cells, or 3.6 (4.2)   107 CD4 CD25  T cells; numbers in parentheses 
denote the amount of cells transferred in AT-EAE (see Fig. 4 B). EAE was 
induced in recipient animals by active immunization with gpMBP in CFA 
(A) or by adoptive transfer of encephalitogenic T cell line cells (B). These 
experiments were reproduced twice with similar results. Generation of 
protective CD4 CD25  T reg cells is related to the application of superag-
onistic CD28-specific mAb and is antigen priming-independent (C). On the 
day of immunization with gpMBP in CFA, animals received 6   107 JJ316-
primed total draining LNCs (open squares) or 6   106 separated MODULATION OF EAE WITH CD28 SUPERAGONISTS | Beyersdorf et al. 452
level. This allowed us to provide the first phenotypical anal-
ysis of rat CD4 CD25 FoxP3  T reg cells (Fig. 3). The vast
majority of CD4 CD25  cells, and all CD4 CD25high cells,
expressed FoxP3 in the steady state and after CD28 superag-
onist stimulation in vivo; this unambiguously identified
them as bona fide T reg cells (Fig. 3). Furthermore, we ex-
tended those previous studies using a standard dose of CD28
superagonist (11, 15) by titrating its amount in vivo to iden-
tify a therapeutic window with as little generalized lympho-
cytosis as possible.
Low-dose CD28 superagonist treatment was sufficient to
increase the pool of CD4 CD25  T reg cells, but did not in-
duce an increase in Tconv cell numbers that is seen regularly
with high dosages (Fig. 1). Therefore, low-dose application of
superagonistic anti-CD28 mAbs provides a very attractive
therapeutic strategy for the treatment of autoimmune diseases.
As to the reasons for the differential response of T reg
and Tconv cells to low-dose superagonistic CD28 treatment,
we hypothesize that T reg cells may be more susceptible to
this form of stimulation because they might receive a “first”
signal constitutively by way of interaction of their autoreac-
tive T cell receptor (26) with self-peptide/MHC complexes.
It can be postulated further that T reg cells that are stimu-
lated by CD28 superagonists in vivo actively suppress the
proliferation of Tconv cells. In line with this possibility, super-
agonistic CD28 stimulation in vitro was sufficient for freshly
isolated T reg cells to suppress the proliferation of Tconv cells
partially (unpublished data). Moreover, CD28-derived sig-
nals are known to be essential for the survival of T reg cells
(27, 28), and it may be that interfering with their natural
turnover by supplying optimized CD28 signals contributes
to their numeric expansion. We recently showed that T cell
activation by CD28 superagonists is superior to conventional
costimulation in protecting from apoptotic cell death (29).
Upon injection of a low dose of mAb JJ316 (0.1 mg), ab-
solute numbers of T reg cells were increased significantly in
the spleen, but not in peripheral lymph nodes. Because this
low dose of antibody was administered i.v., it could be that
only antibody concentrations in the spleen reached sufficient
levels to cause an increase in absolute cell numbers. The ob-
served differences also may be due to better Fc receptor–
mediated cross-linking of the antibody by splenic APCs, which
was shown to be essential for superagonistic CD28 stimula-
tion to function (11). Alternatively, differential migratory
properties of lymph node and splenic T cells upon JJ316
treatment could account for the observed differences. Low-
dose treatment, however, was sufficient to increase the rela-
tive numbers of T reg cells among CD4  cells to near maxi-
mum levels, (i.e., two- to fourfold). As shown in animal
models of allotransplantation (30) and type I diabetes (31),
the ratio of T reg cells/Tconv cells in the microenvironment
of the target organ seems to determine the outcome of the
immune response.
Apart from absolute or relative numbers, suppressor po-
tency at the single cell level is believed to be critical for the
functional balance between T reg cells and their targets (8).
Superagonistic CD28 treatment induces CD25brightCTLA-
4brightFoxP3 CD4  cells with greatly enhanced suppressor
functions, whereas CD25 CD4  cells that were isolated
from the same animals were not suppressive (Fig. 4).
The greatly increased expression of CTLA-4 on T reg
cells after high-dose JJ316-treatment (Fig. 3) may explain
their strong suppressive activity (21, 32). CTLA-4 was
shown to be an effector molecule of T reg cells (21) in-
volved in direct suppression of other T cells (33), and in ren-
dering dendritic cells tolerogenic (34). Additionally, the im-
munosuppressive cytokine, IL-10, which is known to be an
important mediator of T reg cell effector functions (35)—at
least in vivo—is synthesized by JJ316-activated T reg cells in
vitro (15), and is induced strongly upon CD28 superagonist
treatment in vivo (reference 14 and unpublished data). Thus,
the suppressive function of JJ316-activated T reg cells in
vivo may be mediated, at least in part, by IL-10.
The increase in the suppressive potency of T reg cells in
response to CD28 superagonist stimulation probably is
caused indirectly by IL-2 or IL-4, which were shown to be
produced by Tconv cells upon high-dose CD28 superagonist
treatment in vivo (14). Both cytokines are capable of
strongly enhancing the suppressive potency of T reg cells in
vitro and in vivo (36, 37).
The promising data obtained with healthy animals
prompted us to extend our experiments to models of acute
or relapsing central nervous system (CNS) autoimmunity. In
a previous report, we showed that high-dose superagonistic
CD28 treatment had a beneficial prophylactic and therapeu-
tic effect on the peripheral nervous system autoimmune dis-
ease, experimental autoimmune neuritis, of the Lewis rat
(38). Because even very low dosages of the CD28 superago-
nist expanded and activated T reg cells of normal Lewis rats
(Fig. 1), we focused on using different dosages of the CD28
superagonist for the treatment of EAE. In analogous models
of EAE in the mouse, a protective role for T reg cells has
been established (39–41). Superagonistic CD28 therapy
strongly down-modulated disease activity over a wide range
of dosages (Fig. 5), including the low doses that selectively
induced T reg cell expansion. At face value, it is surprising
that the lowest dose of CD28 superagonist used—0.1 mg per
animal—was as efficient in interfering with Lewis rat EAE as
was the 10-fold higher dose which induced a much more
pronounced expansion of T reg cells and a more potent sup-
pressive activity per cell as read out in vitro. Possibly, at 1
mg per animal, the increase in activated CD4 CD25low
FoxP3  effector T cells (Fig. 3) counterbalances the protec-
tive effect that is mediated by a highly active and expanded
T reg cell population to a certain degree.
CNS inflammation is driven by MBP-specific T cells in
EAE of the Lewis rat (25). Therefore, we analyzed T reg
cells from gpMBP-immunized animals that were treated
with the CD28 superagonist or remained untreated with re-
gard to their suppressive capacity toward MBP-specific T
cells in vitro. The failure to detect suppression of gpMBP-
specific T cells by T reg cells from gpMBP-immunized, butJEM VOL. 202, August 1, 2005 453
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otherwise untreated, animals correlates with the inability of
endogenous suppressor cells to prevent disease development
in this immunization scheme. However, T reg cells that
were derived from animals after high- or low-dose CD28
superagonist treatment showed clear suppression of MBP-
specific Tconv cells. Suppression by CD28 superagonist–acti-
vated T reg cells was not restricted to the surrogate in vi-
tro assay. Upon adoptive transfer, JJ316/gpMBP-primed
CD4 CD25  T reg cells protected naive recipients from
EAE (Fig. 7). These activated T reg cells did not have to be
present during the induction phase of the effector T cells be-
cause they also suppressed adoptive transfer EAE (Fig. 7).
Similar to the in vitro suppression assay, transfer of 10
times more Tconv cells had no impact on the course of EAE
(Fig. 7). Therefore, activation and expansion of T reg cells
seems to be the mechanism that underlies the protective effect
of JJ316 in EAE. Moreover, there is no evidence that this
mechanism is complemented by activation-induced cell death
of effector T cells because we did not observe increased num-
bers of apoptotic T cells in tissue sections of the CNS (Fig.
S2), and we could detect gpMBP-responsive effector T cells
in vitro after JJ316-therapy in vivo (Fig. 6 and not depicted).
Technical reasons allowed us to transfer only up to 6  
106 purified T reg cells per animal; i.e.,  5% were added to
the pool of T reg cells that is assumed to be present in the re-
cipient. With these small numbers of transferred cells, only
strongly activated T reg cells can be expected to exert an ef-
fect. Accordingly, we used T reg cells that were activated by
1 mg JJ316 in vivo, which we had found to possess very high
regulatory activity per cell. These were able to ameliorate
clinical signs of EAE, whereas T reg cells that were derived
from low-dose JJ316-treated animals were not (Fig. 7 and not
depicted). Inclusion of gpMBP in the priming protocol was
not necessary for CD28 superagonist–activated T reg cells to
suppress MBP-specific Tconv cells in vitro (not depicted), or
to protect from EAE in vivo (Fig. 7). Although this suggests
that the preexisting natural TCR repertoire of T reg cells
contains a sufficient frequency of cells that is autoreactive to
self-antigens in the CNS, it remains to be solved whether the
therapeutic effect that was observed in vivo is mediated
largely by T reg cells with specificity for the autoantigen
MBP, or achieved mainly by way of bystander suppression by
T reg cells recognizing other autoantigens (39, 40).
Immunohistochemical analyses corroborated our find-
ings, and revealed a decrease in T cell and macrophage infil-
tration into the spinal cord of DA rats protected from the
first episode of EAE by JJ316 treatment (Fig. S1 and Fig. 5
A). However, in this therapeutic regimen, protection was
not observed during the subsequent relapse, which was of
similar severity as in control rats based on clinical appearance
and histology (Fig. S1 and Fig. 5 A). This suggests that at
least in this model, CD28 superagonist–activated T reg cells
suppress encephalitogenic T cells in peripheral lymphoid tis-
sues, and thereby, reduce cellular infiltrates into the CNS. In
gpMBP-induced EAE of the Lewis rat, however, JJ316 ther-
apy did not reduce T cell infiltration into the spinal cord,
and even strongly increased the number of infiltrating mac-
rophages (unpublished data). Here, suppression of the patho-
genic T cells by T reg cells in situ is the likely mechanism
that underlies regulation of the T cell response by JJ316. As
far as macrophage infiltration into the spinal cord after CD28
superagonist treatment is concerned, we hypothesize that
these macrophages could have undergone so-called “alterna-
tive activation.” The cytokines IL-4 and IL-13 were respon-
sible for this alternative activation of macrophages that led to
the production of antiinflammatory cytokines by the macro-
phage (42). Because IL-4-synthesis is induced upon superag-
onistic anti-CD28 stimulation in vivo (14), it is possible that
the macrophages that infiltrate the CNS after JJ316 treat-
ment contribute to the prevention of tissue damage, rather
than augment it.
Finally, we believe that superagonistic CD28-specific
mAbs are very promising tools for targeting and manipulat-
ing CD4 CD25  T reg cells in vivo. Our findings provide
the basis for new therapies to treat MS—and perhaps other
human autoimmune diseases—successfully.
MATERIALS AND METHODS
Animals. Normal Lewis rats were bred at the animal facility of the Institute
for Virology and Immunobiology, University of Würzburg, and were used
for experiments between 6 and 12 wk of age. EAE was induced and moni-
tored in female DA and Lewis rats that were 6–8 wk of age and with a body
weight of 120–140 g, that were obtained from Charles River Wiga. They
were taken at random from individual cages to receive either treatment. All
experiments were performed according to the Bavarian state regulations for
animal experimentation, and were approved by the responsible authorities.
In experiments with histologic analyses, rats were anesthetized with
200 mg/kg body weight pentobarbital (Narcoren; Rhone Merieux) that
was perfused through the left cardiac ventricle with PBS. Spinal cords were
removed, and the tissue was embedded in OCT compound (Sakura
Finetek) for cryopreservation at  80 C.
Purification of CD4 CD25  (T reg) and CD4 CD25  T cells
(Tconv). Routinely, single-cell suspensions were prepared from inguinal,
axillary, cervical, mesenteric, and paraortic lymph nodes, and T cell subsets
were purified using MACS (Miltenyi Biotec) separation columns according
to the manufacturer’s instructions. To remove CD8  T cells and B cells,
lymph node cells were incubated with a biotinylated mAb against CD8
(clone OX8 or G28, BD Biosciences) and biotinylated polyclonal mouse-
anti–rat Ig (Dianova) followed by streptavidin microbeads (Miltenyi Bio-
tec). CD8 Ig  lymph node cells (CD4  T cells) were stained consecutively
with anti-CD25-FITC mAb (clone OX39, Serotec) and anti-FITC micro-
beads (Miltenyi Biotec). Cell purities of regulatory CD25  T cells and con-
ventional CD25  T cells were, on average, 85 and 95%, respectively.
In vitro suppression assays. Cultures of purified T cells were set up in
96-well flat bottom plates (Costar) with cell densities of 5   105 cells/ml in
x-vivo 15 medium (Bio Whittaker) supplemented with 15% heat-inacti-
vated FCS, 1 mM sodium pyruvate, nonessential amino acids, 100 U/ml
penicillin and streptomycin, 30  M mercaptoethanol, and 2 mM L-gluta-
mine (all from GIBCO BRL). To test for suppressor function of T reg cells,
conventional CD4 CD25  T cells or whole CD4  T cells were used as in-
dicator cells and cocultured with different numbers of T reg cells. The T
cells were stimulated with anti-TCR (clone R73) plus anti-CD28 immobi-
lized at a 2:1 ratio on Dynabeads (Dynal) used at a bead/cell ratio of 5:1. Al-
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or spleen cells as APCs (5   105 cells/ml) and Con A (2  g/ml, Sigma-
Aldrich). Proliferation was measured by flow cytometric determination of
dye dilution in CFSE-labeled (5  M; Molecular Probes) Tconv cells or by
measuring [3H]thymidine (Amersham Biosciences) incorporation during the
final 16 h of a 3-d culturing period. The DNA of [3H]thymidine-pulsed
cells was harvested onto fiberglass filters, and the radioactive content was
quantitated using a  -scintillation counter.
To measure suppression of gpMBP-specific Tconv cells by T reg cells, an-
imals were immunized with guinea gpMBP in CFA as for active EAE induc-
tion. 6 d after immunization, the animals were treated with PBS or 0.1 or 1
mg of mAb JJ316. After a further 3 d, T cells were purified from the draining
lymph nodes and restimulated in vitro in the presence of 10  g/ml gpMBP
and irradiated splenic APCs. Co-cultures consisted of 5   104 indicator T
cells (CD4 CD25  from the PBS animal) and 5   104, 104, or 5   103 T reg
cells, or 5   104 CD4 CD25  T cells from the respective animal.
In vivo monitoring of T reg cell proliferation. Lymph node cells and
erythrocyte-depleted spleen cells of five normal Lewis rats were pooled and
passed over nylon wool columns. CD4 CD25  and CD4 CD25  T cells
were purified from the nylon wool nonadherent fraction using MACS col-
umns. Purified cells were washed extensively with protein-free balanced salt
solution and labeled with 5  M CFSE for 5 min at room temperature in the
dark. The cells were washed twice with fully supplemented x-vivo 15 me-
dium containing 15% FCS. The cells were resuspended in sterile PBS and
transferred i.v. (CD4 CD25 : 106 per animal; CD4 CD25 : 5   106 per
animal). On the following day, 0.1 or 1 mg of mAb JJ316 or 1.0 mg of iso-
type-control mAb MOPC-31C was injected i.v. into the tail vein. Recipi-
ent animals were killed on day three after cell transfer, and nylon wool non-
adherent cells were isolated from pooled spleen and lymph nodes before
staining for CD4 and CD25 expression.
FACS analysis. The following monoclonal antibodies were used: anti–rat
CD4-CyChrome (clone OX35, BD Biosciences); anti–rat CD25-FITC or
-biotin (clone Ox39); anti–rat CTLA-4–biotin (clone WKH203, all Sero-
tec), and anti–mouse FoxP3 (clone mFOXY, eBioscience).
For FACS analysis, up to 106 cells resuspended in 50  l of PBS/0.1%
BSA/0.02% NaN3 were incubated with 20  g/ml of normal mouse Ig
(Sigma-Aldrich) to block unspecific Fc-receptor binding (15 min, 4 C). Af-
ter the blocking step, FITC-, PE-, and CyChrome-conjugated or biotinyl-
ated mAbs were added (15 min, 4 C). Bound biotinylated antibodies were
detected by incubation with CyChrome- or allophycocyanin-conjugated
streptavidin (BD Biosciences). The cells were analyzed after a final washing
step on a FACScan or FACSCalibur flow cytometer using Cell Quest soft-
ware (all Becton Dickinson). Dot plots and histograms are shown as log10
fluorescence intensities on a 4-decade scale.
Intracellular staining for FoxP3 and CTLA-4 expression was performed
by incubating impermeabilized cells with FITC- and APC-conjugated anti-
bodies and washing them once with ice-cold PBS before fixing them for 30
min at room temperature with fixation buffer (eBioscience). Cells were per-
meabilized (permeabilization buffer, eBisocience) before incubation with
anti–CTLA-4 mAb (WKH203-biotin) and anti-FoxP3 mAb (mFOXY-PE)
for 30 min at room temperature. Specificity of anti–CTLA-4 staining was
verified by blockade with 100  g/ml unconjugated mAb WKH203.
Induction of EAE. Lewis or DA rats were inoculated in one of the hind
footpads with 50  l of an emulsion containing equal volumes of 100  g of
gpMBP or recombinant human MOG (43) in saline and CFA with Myco-
bacterium tuberculosis (0.5 mg/ml; Difco). I.v. treatment with mAbs JJ316,
MOPC-31C or JJ319 was as indicated for individual experiments. In the
case of adoptive transfer of in vivo primed lymphocytes cells were also in-
jected i.v. Methylprednisolone (Urbason, Aventis) was given to Lewis rats
at a dose of 2 mg per animal and day from days 11 to 15 after immunization.
AT-EAE was induced by i.v. injection of 8   106 gpMBP-specific
CD4  activated T cells into Lewis rats (44). Animals were weighed and in-
spected for disease severity on a daily basis. Clinical scoring was performed as
follows: 0   normal; 1   impaired righting/limp tail; 2   atactic gait/abnor-
mal position; 3   moderate paraparesis; 4   tetraplegia; and 5   death.
Detection of FoxP3 by Western blot analysis. T reg and Tconv cells
were purified from JJ316-treated or untreated animals (control) as described
before. Whole cells were lysed using 2x Laemmli buffer. SDS-PAGE was
used for protein separation followed by protein blotting onto a polyvinylidene
difluoride membrane (Millipore). FoxP3 protein expression was detected
with a polyclonal rabbit anti–mouse-FoxP3 IgG (gift of A.Y. Rudensky).
Protein loading was assessed by detecting ERK-2 expression with a poly-
clonal rabbit/goat-anti–rat-ERK-2 Ig (Santa Cruz Biotechnology, Inc.).
Statistical analyses. Data were subjected to Mann-Whitney rank sum
tests or ANOVA (Prism 3.0, GraphPad software) where indicated in the
text. p-values of  0.05 were considered to be significant; p-values of  0.01
were considered to be highly significant.
Online supplemental material. Fig. S1 depicts immunohistochemical
data showing reduced T cell and macrophage infiltration in the CNS and
less demyelination in animals that were protected from EAE by JJ316. Fig.
S2 provides data that JJ316 also protects Lewis rats from clinical signs of
AT-EAE. Online supplemental material is available at http://www.jem.
org/cgi/content/full/jem.20051060/DC1.
The authors thank M. Herold and C. Kraus for help with Western blotting procedures. 
We thank G. Köllner, V. Wörtmann, H. Brünner, and M. Friedrich for expert technical 
assistance.
This work was funded by a joint grant from TeGenero ImmunoTherapeutics AG 
and the Bayerische Forschungsstiftung (forimmun), and by IZKF Würzburg 01 KS 
903/Teilprojekt C13 (BMBF).
T. Hünig and T. Kerkau declare a commercial interest in TeGenero 
ImmunoTherapeutics AG. They are among the cofounders and shareholders of 
TeGenero, which develops CD28 superagonists for clinical use. T. Hünig and T. Kerkau 
are scientific advisors to TeGenero. The authors have no other potential conflicting 
financial interests.
Submitted: 25 May 2005
Accepted: 24 June 2005
REFERENCES
1. Walker, L.S., and A.K. Abbas. 2002. The enemy within: keeping self-
reactive T cells at bay in the periphery. Nat. Rev. Immunol. 2:11–19.
2. Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh, and M. Toda. 1995. Im-
munologic self-tolerance maintained by activated T cells expressing IL-2
receptor alpha-chains (CD25). Breakdown of a single mechanism of self-
tolerance causes various autoimmune diseases. J. Immunol. 155:1151–1164.
3. Suri-Payer, E., A.Z. Amar, A.M. Thornton, and E.M. Shevach. 1998.
CD4 CD25  T cells inhibit both the induction and effector function
of autoreactive T cells and represent a unique lineage of immunoregu-
latory cells. J. Immunol. 160:1212–1218.
4. Dieckmann, D., C.H. Bruett, H. Ploettner, M.B. Lutz, and G.
Schuler. 2002. Human CD4( )CD25( ) regulatory, contact-depen-
dent T cells induce interleukin 10-producing, contact-independent
type 1-like regulatory T cells. J. Exp. Med. 196:247–253.
5. Jonuleit, H., E. Schmitt, M. Stassen, A. Tuettenberg, J. Knop, and
A.H. Enk. 2001. Identification and functional characterization of hu-
man CD4( )CD25( ) T cells with regulatory properties isolated from
peripheral blood. J. Exp. Med. 193:1285–1294.
6. Sakaguchi, S. 2000. Regulatory T cells: key controllers of immuno-
logic self-tolerance. Cell. 101:455–458.
7. Kukreja, A., G. Cost, J. Marker, C. Zhang, Z. Sun, K. Lin-Su, S. Ten,
M. Sanz, M. Exley, B. Wilson, et al. 2002. Multiple immuno-regula-
tory defects in type-1 diabetes. J. Clin. Invest. 109:131–140.
8. Viglietta, V., C. Baecher-Allan, H.L. Weiner, and D.A. Hafler. 2004.
Loss of functional suppression by CD4 CD25  regulatory T cells in
patients with multiple sclerosis. J. Exp. Med. 199:971–979.
9. Ehrenstein, M.R., J.G. Evans, A. Singh, S. Moore, G. Warnes, D.A.JEM VOL. 202, August 1, 2005 455
ARTICLE
Isenberg, and C. Mauri. 2004. Compromised function of regulatory T
cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J.
Exp. Med. 200:277–285.
10. Kriegel, M.A., T. Lohmann, C. Gabler, N. Blank, J.R. Kalden, and
H.M. Lorenz. 2004. Defective suppressor function of human CD4 
CD25  regulatory T cells in autoimmune polyglandular syndrome
type II. J. Exp. Med. 199:1285–1291.
11. Tacke, M., G. Hanke, T. Hanke, and T. Hunig. 1997. CD28-medi-
ated induction of proliferation in resting T cells in vitro and in vivo
without engagement of the T cell receptor: evidence for functionally
distinct forms of CD28. Eur. J. Immunol. 27:239–247.
12. Luhder, F., Y. Huang, K.M. Dennehy, C. Guntermann, I. Muller, E.
Winkler, T. Kerkau, S. Ikemizu, S.J. Davis, T. Hanke, and T. Hunig.
2003. Topological requirements and signaling properties of T cell-acti-
vating, anti-CD28 antibody superagonists. J. Exp. Med. 197:955–966.
13. Evans, E.J., R.M. Esnouf, R. Manso-Sancho, R.J. Gilbert, J.R. James,
C. Yu, J.A. Fennelly, C. Vowles, T. Hanke, B. Walse, et al. 2005. Crys-
tal structure of a soluble CD28-Fab complex. Nat. Immunol. 6:271–279.
14. Rodriguez-Palmero, M., T. Hara, A. Thumbs, and T. Hunig. 1999.
Triggering of T cell proliferation through CD28 induces GATA-3 and
promotes T helper type 2 differentiation in vitro and in vivo. Eur. J.
Immunol. 29:3914–3924.
15. Lin, C.H., and T. Hunig. 2003. Efficient expansion of regulatory T
cells in vitro and in vivo with a CD28 superagonist. Eur. J. Immunol.
33:626–638.
16. Fontenot, J.D., M.A. Gavin, and A.Y. Rudensky. 2003. Foxp3 pro-
grams the development and function of CD4 CD25  regulatory T
cells. Nat. Immunol. 4:330–336.
17. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell
development by the transcription factor Foxp3. Science. 299:1057–1061.
18. Khattri, R., T. Cox, S.A. Yasayko, and F. Ramsdell. 2003. An essential
role for Scurfin in CD4 CD25  T regulatory cells. Nat. Immunol.
4:337–342.
19. Fontenot, J.D., J.P. Rasmussen, L.M. Williams, J.L. Dooley, A.G. Farr,
and A.Y. Rudensky. 2005. Regulatory T cell lineage specification by
the forkhead transcription factor foxp3. Immunity. 22:329–341.
20. Takahashi, T., T. Tagami, S. Yamazaki, T. Uede, J. Shimizu, N. Sa-
kaguchi, T.W. Mak, and S. Sakaguchi. 2000. Immunologic self-toler-
ance maintained by CD25( )CD4( ) regulatory T cells constitutively
expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med.
192:303–310.
21. Read, S., V. Malmstrom, and F. Powrie. 2000. Cytotoxic T lympho-
cyte-associated antigen 4 plays an essential role in the function of
CD25( )CD4( ) regulatory cells that control intestinal inflammation.
J. Exp. Med. 192:295–302.
22. Baecher-Allan, C., J.A. Brown, G.J. Freeman, and D.A. Hafler. 2001.
CD4 CD25high regulatory cells in human peripheral blood. J. Immunol.
167:1245–1253.
23. Levings, M.K., R. Sangregorio, C. Sartirana, A.L. Moschin, M. Batta-
glia, P.C. Orban, and M.G. Roncarolo. 2002. Human CD25 CD4 
T suppressor cell clones produce transforming growth factor beta, but
not interleukin 10, and are distinct from type 1 T regulatory cells. J.
Exp. Med. 196:1335–1346.
24. Pozzilli, C., F. Marinelli, S. Romano, and F. Bagnato. 2004. Cortico-
steroids treatment. J. Neurol. Sci. 223:47–51.
25. Swanborg, R.H. 2001. Experimental autoimmune encephalomyelitis
in the rat: lessons in T-cell immunology and autoreactivity. Immunol.
Rev. 184:129–135.
26. Hsieh, C.S., Y. Liang, A.J. Tyznik, S.G. Self, D. Liggitt, and A.Y.
Rudensky. 2004. Recognition of the peripheral self by naturally arising
CD25  CD4  T cell receptors. Immunity. 21:267–277.
27. Salomon, B., D.J. Lenschow, L. Rhee, N. Ashourian, B. Singh, A.
Sharpe, and J.A. Bluestone. 2000. B7/CD28 costimulation is essential
for the homeostasis of the CD4 CD25  immunoregulatory T cells
that control autoimmune diabetes. Immunity. 12:431–440.
28. Tang, Q., K.J. Henriksen, E.K. Boden, A.J. Tooley, J. Ye, S.K. Subu-
dhi, X.X. Zheng, T.B. Strom, and J.A. Bluestone. 2003. Cutting edge:
CD28 controls peripheral homeostasis of CD4 CD25  regulatory T
cells. J. Immunol. 171:3348–3352.
29. Kerstan, A., and T. Hunig. 2004. Cutting edge: distinct TCR- and
CD28-derived signals regulate CD95L, Bcl-xL, and the survival of pri-
mary T cells. J. Immunol. 172:1341–1345.
30. Cobbold, S.P., R. Castejon, E. Adams, D. Zelenika, L. Graca, S.
Humm, and H. Waldmann. 2004. Induction of foxP3  regulatory T
cells in the periphery of T cell receptor transgenic mice tolerized to
transplants. J. Immunol. 172:6003–6010.
31. Peng, Y., Y. Laouar, M.O. Li, E.A. Green, and R.A. Flavell. 2004.
TGF-beta regulates in vivo expansion of Foxp3-expressing CD4 
CD25  regulatory T cells responsible for protection against diabetes.
Proc. Natl. Acad. Sci. USA. 101:4572–4577.
32. Maloy, K.J., and F. Powrie. 2001. Regulatory T cells in the control of
immune pathology. Nat. Immunol. 2:816–822.
33. Paust, S., L. Lu, N. McCarty, and H. Cantor. 2004. Engagement of B7
on effector T cells by regulatory T cells prevents autoimmune disease.
Proc. Natl. Acad. Sci. USA. 101:10398–10403.
34. Fallarino, F., U. Grohmann, K.W. Hwang, C. Orabona, C. Vacca, R.
Bianchi, M.L. Belladonna, M.C. Fioretti, M.L. Alegre, and P. Puccetti.
2003. Modulation of tryptophan catabolism by regulatory T cells. Nat.
Immunol. 4:1206–1212.
35. O’Garra, A., P.L. Vieira, P. Vieira, and A.E. Goldfeld. 2004. IL-10-
producing and naturally occurring CD4  Tregs: limiting collateral
damage. J. Clin. Invest. 114:1372–1378.
36. Furtado, G.C., M.A. Curotto de Lafaille, N. Kutchukhidze, and J.J.
Lafaille. 2002. Interleukin 2 signaling is required for CD4( ) regula-
tory T cell function. J. Exp. Med. 196:851–857.
37. Thornton, A.M., E.E. Donovan, C.A. Piccirillo, and E.M. Shevach. 2004.
Cutting edge: IL-2 is critically required for the in vitro activation of
CD4 CD25  T cell suppressor function. J. Immunol. 172:6519–6523.
38. Schmidt, J., K. Elflein, M. Stienekemeier, M. Rodriguez-Palmero, C.
Schneider, K.V. Toyka, R. Gold, and T. Hunig. 2003. Treatment and
prevention of experimental autoimmune neuritis with superagonistic
CD28-specific monoclonal antibodies. J. Neuroimmunol. 140:143–152.
39. Hori, S., M. Haury, A. Coutinho, and J. Demengeot. 2002. Specificity
requirements for selection and effector functions of CD25 4  regula-
tory T cells in anti-myelin basic protein T cell receptor transgenic
mice. Proc. Natl. Acad. Sci. USA. 99:8213–8218.
40. Reddy, J., Z. Illes, X. Zhang, J. Encinas, J. Pyrdol, L. Nicholson, R.A.
Sobel, K.W. Wucherpfennig, and V.K. Kuchroo. 2004. Myelin pro-
teolipid protein-specific CD4 CD25  regulatory cells mediate ge-
netic resistance to experimental autoimmune encephalomyelitis. Proc.
Natl. Acad. Sci. USA. 101:15434–15439.
41. Kohm, A.P., P.A. Carpentier, H.A. Anger, and S.D. Miller. 2002.
Cutting edge: CD4 CD25  regulatory T cells suppress antigen-spe-
cific autoreactive immune responses and central nervous system inflam-
mation during active experimental autoimmune encephalomyelitis. J.
Immunol. 169:4712–4716.
42. Gordon, S. 2003. Alternative activation of macrophages. Nat. Rev. Im-
munol. 3:23–35.
43. Weishaupt, A., S. Jander, W. Bruck, T. Kuhlmann, M. Stienekemeier,
T. Hartung, K.V. Toyka, G. Stoll, and R. Gold. 2000. Molecular
mechanisms of high-dose antigen therapy in experimental autoimmune
encephalomyelitis: rapid induction of Th1-type cytokines and induc-
ible nitric oxide synthase. J. Immunol. 165:7157–7163.
44. Gold, R., G. Giegerich, H.P. Hartung, and K.V. Toyka. 1995. T-cell
receptor (TCR) usage in Lewis rat experimental autoimmune enceph-
alomyelitis: TCR beta-chain-variable-region V beta 8.2-positive T
cells are not essential for induction and course of disease. Proc. Natl.
Acad. Sci. USA. 92:5850–5854.